Holen Sie sich die Stockscreener-App
110.64
1.62%
-1.82
Vorhandelsmarkt:
111.00
0.36
+0.33%
Schlusskurs vom Vortag:
$112.46
Offen:
$112.83
24-Stunden-Volumen:
421.42K
Relative Volume:
0.59
Marktkapitalisierung:
$7.12B
Einnahmen:
$74.06M
Nettoeinkommen (Verlust:
$-114.71M
KGV:
-61.33
EPS:
-1.8039
Netto-Cashflow:
$-117.90M
1W Leistung:
+4.51%
1M Leistung:
+8.28%
6M Leistung:
+20.87%
1J Leistung:
+102.41%
1-Tages-Spanne:
$108.53
$113.66
1-Wochen-Bereich:
$104.89
$113.66
52-Wochen-Spanne:
$49.38
$113.66
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Firmenname
Protagonist Therapeutics Inc
Sektor
Branche
Telefon
(510) 474-0170
Adresse
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
110.64 | 7.23B | 74.06M | -114.71M | -117.90M | -1.8039 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-12 | Eingeleitet | Leerink Partners | Outperform |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-12-06 | Eingeleitet | Goldman | Neutral |
| 2024-11-05 | Eingeleitet | Wedbush | Outperform |
| 2024-09-24 | Eingeleitet | TD Cowen | Buy |
| 2024-09-09 | Eingeleitet | Truist | Buy |
| 2023-10-30 | Eingeleitet | CapitalOne | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Buy |
| 2021-10-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-24 | Eingeleitet | Northland Capital | Outperform |
| 2021-01-06 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-15 | Eingeleitet | Jefferies | Buy |
| 2020-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-05-09 | Hochstufung | Stifel | Hold → Buy |
| 2018-12-06 | Eingeleitet | Nomura | Buy |
| 2018-01-29 | Eingeleitet | Stifel | Buy |
| 2017-07-21 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Wall Street Says Johnson And Johnson’s FDA-Approved Psoriasis Drug Should Create 'Significant Value’ For Protagonist Therapeutics - Stocktwits
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
NEXTBio Capital Management LP Takes Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal (NASDAQ:PTGX) - Seeking Alpha
Keystone Investors PTE Ltd. Buys Shares of 26,390 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Shows Technical Strength and High Growth Momentum - ChartMill
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data - Benzinga
Protagonist Therapeutics director Waddill sells $969,120 in shares By Investing.com - Investing.com Canada
Protagonist Therapeutics director Waddill sells $969,120 in shares - Investing.com
Protagonist Therapeutics (NASDAQ: PTGX) director exercises 9,000 options, sells 9,000 shares under 10b5-1 plan - Stock Titan
PTGX Stock Quote Price and Forecast - CNN
571,825 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. - MarketBeat
Protagonist Therapeutics stock hits all-time high at 107.86 USD By Investing.com - Investing.com Nigeria
PTGX (NASDAQ) insider 10b5-1 sale of 9,000 shares; option exercise noted - Stock Titan
PTGX: Icotyde's strong launch and a robust pipeline drive growth, with Rusfertide approval expected soon - TradingView
Protagonist Therapeutics stock hits all-time high at 107.86 USD - Investing.com
Protagonist Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Clearbridge Investments LLC Buys Shares of 489,842 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics Jumps 6.3% Amid Sector-Wide Rally - AlphaStreet
BNP Paribas Financial Markets Has $8.54 Million Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 - Salinas Californian
Protagonist Therapeutics, Inc. - MLQ.ai
Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why - MSN
Assessing Protagonist Therapeutics (PTGX) Valuation After Positive Rusfertide Data And Icotyde Approval News - Sahm
Avoiding Lag: Real-Time Signals in (PTGX) Movement - Stock Traders Daily
Geode Capital Management LLC Boosts Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Citizens raises Protagonist Therapeutics stock price target on platform validation - Investing.com
Protagonist Therapeutics Jumps 6.1% Amid Sector-Wide Rally - AlphaStreet
PTGX: Robust royalties, pipeline progress, and share buyback plans drive strong growth outlook - TradingView
Protagonist Therapeutics director Waddill sells $896,760 in common stock By Investing.com - Investing.com South Africa
Protagonist Therapeutics director Waddill sells $896,760 in common stock - Investing.com
Director at Protagonist Therapeutics (PTGX) sells shares after exercising options - Stock Titan
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress - ACCESS Newswire
Rusfertide results in polycythemia vera at European hematology congress - Stock Titan
Jefferies Financial Group Inc. Sells 816,503 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - MSN
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
[144] Protagonist Therapeutics, Inc SEC Filing - Stock Titan
Fisher Asset Management LLC Makes New Investment in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (PTGX) Falls 1.76%; Stock Holds Above $95 Support Amid Biotech VolatilityGrowth ETF - The Legal Advocate
Protagonist Therapeutics to Present at Two Investment Bank Conferences in June 2026 - geneonline.com
Protagonist Therapeutics (PTGX) Stock Forecast & Analyst Ratings - Moomoo
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026 - ACCESS Newswire
Protagonist CEO schedules two June healthcare conference talks - Stock Titan
PTGXProtagonist Therapeutics Inc Stock Price and Quote - Finviz
Discipline and Rules-Based Execution in PTGX Response - Stock Traders Daily
PTGX Stock Price, Quote & Chart | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
Protagonist Therapeutics (NASDAQ:PTGX) Upgraded to "Strong-Buy" at Wolfe Research - MarketBeat
Wolfe Research initiates Protagonist Therapeutics stock with outperform rating - Investing.com India
Wolfe Research initiates Protagonist Therapeutics stock with outperform rating By Investing.com - Investing.com India
Finanzdaten der Protagonist Therapeutics Inc-Aktie (PTGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Protagonist Therapeutics Inc-Aktie (PTGX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Waddill William D. | Director |
Jun 10 '26 |
Sale |
107.68 |
9,000 |
969,120 |
7,825 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):